FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * GEMAYEL GEORGES 2. Issuer Name and Ticker or Trading Symbol Gemini Therapeutics, Inc. /DE [ GMTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O GEMINI THERAPEUTICS, INC., 300 ONE KENDALL SQUARE, 3RD FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)
4/29/2021
(Street)
CAMBRIDGE,, MA 02139
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $11.92  4/29/2021    A     45466       (1) 4/28/2031  Common Stock  45466  $0  45466  D   

Explanation of Responses:
(1)  This option shall vest and become exercisable over a period of three years from the Vesting Start Date, April 29, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting in eight quarterly installments thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GEMAYEL GEORGES
C/O GEMINI THERAPEUTICS, INC.
300 ONE KENDALL SQUARE, 3RD FLOOR
CAMBRIDGE,, MA 02139
X



Signatures
/s/ Jason Meyenburg, attorney-in-fact 5/3/2021
**Signature of Reporting Person Date
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Gemini Therapeutics Charts.
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Gemini Therapeutics Charts.